TherapeuticsMD Inc (NASDAQ:TXMD) Expected to Post Quarterly Sales of $5.90 Million

Brokerages forecast that TherapeuticsMD Inc (NASDAQ:TXMD) will announce $5.90 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for TherapeuticsMD’s earnings. The lowest sales estimate is $4.89 million and the highest is $8.20 million. TherapeuticsMD posted sales of $3.76 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 56.9%. The company is scheduled to announce its next quarterly earnings report on Monday, July 29th.

According to Zacks, analysts expect that TherapeuticsMD will report full-year sales of $32.15 million for the current financial year, with estimates ranging from $25.87 million to $39.60 million. For the next fiscal year, analysts expect that the company will post sales of $176.44 million, with estimates ranging from $116.60 million to $257.33 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The business had revenue of $3.95 million for the quarter, compared to analyst estimates of $5.96 million. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) EPS.

TXMD has been the topic of several research reports. ValuEngine lowered TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Oppenheimer reissued a “buy” rating on shares of TherapeuticsMD in a research report on Tuesday, March 19th. Zacks Investment Research lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. BidaskClub raised TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. Finally, Jefferies Financial Group dropped their target price on TherapeuticsMD from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. TherapeuticsMD presently has a consensus rating of “Hold” and a consensus price target of $9.41.

Shares of TXMD stock traded down $0.14 on Tuesday, hitting $2.44. 3,251,402 shares of the stock traded hands, compared to its average volume of 3,949,664. The company has a current ratio of 3.39, a quick ratio of 3.28 and a debt-to-equity ratio of 1.26. The firm has a market cap of $588.58 million, a P/E ratio of -4.14 and a beta of 2.14. TherapeuticsMD has a 1-year low of $2.21 and a 1-year high of $7.42.

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in TherapeuticsMD in the first quarter worth $249,000. Amalgamated Bank increased its position in TherapeuticsMD by 145.3% in the fourth quarter. Amalgamated Bank now owns 26,314 shares of the company’s stock worth $100,000 after buying an additional 15,586 shares during the period. Cetera Advisors LLC increased its position in TherapeuticsMD by 13.8% in the first quarter. Cetera Advisors LLC now owns 77,725 shares of the company’s stock worth $380,000 after buying an additional 9,450 shares during the period. Private Ocean LLC acquired a new position in shares of TherapeuticsMD during the first quarter valued at $37,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of TherapeuticsMD by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 30,499,363 shares of the company’s stock valued at $116,202,000 after purchasing an additional 213,444 shares during the period. 78.93% of the stock is currently owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Article: What is the downside to momentum investing?

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.